Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma

Sarcoma

Volumn 2009, Issue , 2009, Pages

  Nielsen, Torsten O ^a   Nguyen, Anne ^a   Su, Le ^a   Campbell, Belinda ^b   Poulin, Neal M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 TERT BUTYLPHENYLSULFONYL) 2 PROPENENITRILE; DOXORUBICIN; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; SMALL INTERFERING RNA; TANESPIMYCIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOASSAY; CANCER CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN TARGETING; SARCOMA CELL; SIGNAL TRANSDUCTION; SYNOVIAL SARCOMA;

EID: 65749094681     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2009/794901     Document Type: Article

References (48)

1. Ladanyi M., Fusions of the SYT and SSX genes in synovial sarcoma Oncogene 2001 20 40 5755 5762 (Pubitemid 32928113)
2. Ferrari A., Gronchi A., Casanova M., Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution Cancer 2004 101 3 627 634 (Pubitemid 38970615)
3. Guillou L., Benhattar J., Bonichon F., Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis Journal of Clinical Oncology 2004 22 20 4040 4050 (Pubitemid 41185173)
4. Takenaka S., Ueda T., Naka N., Prognostic implication of SYT-SSX fusion type in synovial sarcoma: a multi-institutional retrospective analysis in Japan Oncology Reports 2008 19 2 467 476
5. Guadagnolo B., Zagars G., Ballo M., Long-term outcomes for synovial sarcoma treated with conservation surgery and radiotherapy International Journal of Radiation Oncology, Biology, Physics 2007 69 4 1173 1180 (Pubitemid 47625848)
6. Terry J., Lubieniecka J. M., Kwan W., Liu S., Nielsen T. O., Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models Clinical Cancer Research 2005 11 15 5631 5638 (Pubitemid 41060842)
7. Schulte T. W., Blagosklonny M. V., Romanova L., Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway Molecular and Cellular Biology 1996 16 10 5839 5845 (Pubitemid 26315105)
8. Xu W., Mimnaugh E., Rosser M. F. N., Sensitivity of mature ErbB2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90 The Journal of Biological Chemistry 2001 276 5 3702 3708 (Pubitemid 37411676)
9. MxFC;ller P., Ceskova P., Vojtesek B., Hsp90 is essential for restoring cellular functions of temperature-sensitive p53 mutant protein but not for stabilization and activation of wild-type p53: implications for cancer therapy The Journal of Biological Chemistry 2005 280 8 6682 6691 (Pubitemid 40341222)
10. Rahmani M., Reese E., Dai Y., Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ cells sensitive and resistant to STI571 (imatinib mesylate) in association with Down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change Molecular Pharmacology 2005 67 4 1166 1176 (Pubitemid 40416722)
11. Broemer M., Krappmann D., Scheidereit C., Requirement of Hsp90 activity for I x3BA; B kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF- x3BA; B activation Oncogene 2004 23 31 5378 5386 (Pubitemid 39005813)
12. Lewis J., Devin A., Miller A., Disruption of Hsp96 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor- x3BA; B activation The Journal of Biological Chemistry 2000 275 14 10519 10526 (Pubitemid 30202115)
13. Workman P., Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone Cancer Letters 2004 206 2 149 157 (Pubitemid 38317285)
14. Neckers L., Ivy S. P., Heat shock protein 90 Current Opinion in Oncology 2003 15 6 419 424 (Pubitemid 38147036)
15. Solit D. B., Chiosis G., Development and application of Hsp90 inhibitors Drug Discovery Today 2008 13 1-2 38 43
16. Ito T., Ouchida M., Morimoto Y., Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo Cancer Letters 2005 224 2 311 319 (Pubitemid 40725851)
17. Kwan W., Terry J., Liu S., Knowling M., Nielsen T. O., Effect of depsipeptide (NSC 630176), a histone deacetylase inhibitor, on human synovial sarcoma in vitro Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO x27;05) May 2005 Orlando, Fla, USA. abstract 9039
18. Liu S., Cheng H., Kwan W., Lubieniecka J. M., Nielsen T. O., Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models Molecular Cancer Therapeutics 2008 7 6 1751 1761
19. Kouzarides T., Chromatin modifications and their function Cell 2007 128 4 693 705 (Pubitemid 46273577)
20. Marks P. A., Miller T., Richon V. M., Histone deacetylases Current Opinion in Pharmacology 2003 3 4 344 351 (Pubitemid 36908937)
21. Gu W., Roeder R. G., Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain Cell 1997 90 4 595 606 (Pubitemid 27357952)
22. Chen L.-F., Fischle W., Verdin E., Greene W. C., Duration of nuclear NF- x3BA; B action regulated by reversible acetylation Science 2001 293 5535 1653 1657 (Pubitemid 32807844)
23. Yu X., Guo Z. S., Marcu M. G., Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228 Journal of the National Cancer Institute 2002 94 7 504 513 (Pubitemid 34411289)
24. Shankar S., Srivastava R. K., Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis Advances in Experimental Medicine and Biology 2008 615 261 298
25. Ito T., Ouchida M., Ito S., SYT, a partner of SYT-SSX oncoprotein in synovial sarcomas, interacts with mSin3A, a component of histone deacetylase complex Laboratory Investigation 2004 84 11 1484 1490 (Pubitemid 39482165)
26. Lubieniecka J. M., de Bruijn D. R. H., Su L., Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma Cancer Research 2008 68 11 4303 4310
27. Rahmani M., Yu C., Dai Y., Coadministration of the heat shock protein 90 antagonist 17-allylamino-17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells Cancer Research 2003 63 23 8420 8427 (Pubitemid 37549498)
28. George P., Bali P., Annavarapu S., Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3 Blood 2005 105 4 1768 1776 (Pubitemid 40223701)
29. Huang H.-C., Liu Y.-C., Liu S.-H., Tzang B.-S., Lee W.-C., Geldanamycin inhibits trichostatin A-induced cell death and histone H4 hyperacetylation in COS-7 cells Life Sciences 2002 70 15 1763 1775 (Pubitemid 34178362)
30. Yang G., Thompson M. A., Brandt S. J., Hiebert S. W., Histone deacetylase inhibitors induce the degradation of the t (8;21) fusion oncoprotein Oncogene 2007 26 1 91 101 (Pubitemid 46067334)
31. Shishodia S., Aggarwal B. B., Nuclear factor- x3BA; B: a friend or a foe in cancer? Biochemical Pharmacology 2004 68 6 1071 1080 (Pubitemid 39094272)
32. Karin M., Nuclear factor- x3BA; B in cancer development and progression Nature 2006 441 7092 431 436 (Pubitemid 44050137)
33. Albini A., Dellx27;Eva R., VenxE9; R., Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF- x3BA; B and Akt as targets The FASEB Journal 2006 20 3 527 529 (Pubitemid 46671238)
34. Moran S. T., Haider K., Ow Y., Milton P., Chen L., Pillai S., Protein kinase C-associated kinase can activate NF x3BA; B in both a kinase-dependent and a kinase-independent manner The Journal of Biological Chemistry 2003 278 24 21526 21533 (Pubitemid 36792550)
35. Francis P., NamlxF8;s H. M., MxFC;ller C., Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential BMC Genomics 2007 8, article 73 1 16 (Pubitemid 46510277)
36. Mayo M. W., Denlinger C. E., Broad R. M., Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF- x3BA; B through the Akt pathway The Journal of Biological Chemistry 2003 278 21 18980 18989 (Pubitemid 36799282)
37. Kawai A., Naito N., Yoshida A., Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1 Cancer Letters 2004 204 1 105 113 (Pubitemid 38117199)
38. Nojima T., Wang Y.-S., Abe S., Matsuno T., Yamawaki S., Nagashima K., Morphological and cytogenetic studies of a human synovial sarcoma xenotransplanted into nude mice Acta Pathologica Japonica 1990 40 7 486 493 (Pubitemid 20295351)
39. Chou T.-C., Talalay P., Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Advances in Enzyme Regulation 1984 22 27 55
40. Wang X., Ju W., Renouard J., Aden J., Belinsky S. A., Lin Y., 17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor- x3BA; B pathway Cancer Research 2006 66 2 1089 1095 (Pubitemid 43165977)
41. Pierce J. W., Schoenleber R., Jesmok G., Novel inhibitors of cytokine-induced I x3BA; B x3B1; phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo The Journal of Biological Chemistry 1997 272 34 21096 21103 (Pubitemid 27373968)
42. Lubieniecka J. M., Nielsen T. O., cDNA microarray-based translational research in soft tissue sarcoma Journal of Surgical Oncology 2005 92 4 267 271 (Pubitemid 41779280)
43. Ronnen E. A., Kondagunta G. V., Ishill N., A phase II trial of 17-(allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma Investigational New Drugs 2006 24 6 543 546 (Pubitemid 44273031)
44. Goetz M. P., Toft D., Reid J., Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer Journal of Clinical Oncology 2005 23 6 1078 1087 (Pubitemid 46202262)
45. Ryan Q. C., Headlee D., Acharya M., Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma Journal of Clinical Oncology 2005 23 17 3912 3922 (Pubitemid 46218694)
46. Stadler W. M., Margolin K., Ferber S., McCulloch W., Thompson J. A., A phase II study of depsipeptide in refractory metastatic renal cell cancer Clinical Genitourinary Cancer 2006 5 1 57 60
47. Terry J., Saito T., Subramanian S., TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies American Journal of Surgical Pathology 2007 31 2 240 246 (Pubitemid 46175025)
48. Ghosh H. S., Spencer J. V., Ng B., McBurney M. W., Robbins P. D., Sirt1 interacts with transducin-like enhancer of split-1 to inhibit nuclear factor x3BA; B-mediated transcription Biochemical Journal 2007 408 1 105 111 (Pubitemid 350158408)